Stock Events

Stock Events

CureVac N.V.

0

551

+€0.00+0% 00:00 Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

BioNTech SE is a direct competitor in the mRNA technology space, focusing on developing vaccines and therapeutics, similar to CureVac's core business.

Moderna, Inc. is a leader in mRNA therapeutics and vaccines, directly competing with CureVac in the COVID-19 vaccine market and other therapeutic areas.

Pfizer Inc., in collaboration with BioNTech, competes in the mRNA vaccine market, particularly with their COVID-19 vaccine, which is in direct competition with CureVac's development.

Novavax, Inc. competes in the vaccine space, particularly with its protein-based COVID-19 vaccine, offering an alternative to mRNA vaccines like those developed by CureVac.

Johnson & Johnson

Johnson & Johnson competes in the vaccine market with its viral vector COVID-19 vaccine, offering an alternative approach to CureVac's mRNA technology.

AstraZeneca PLC competes with its viral vector COVID-19 vaccine, which is a different technology but serves the same market as CureVac's vaccine candidates.

Sanofi competes in the vaccine and therapeutic market, working on mRNA vaccines and other technologies that could compete with CureVac's products.

GlaxoSmithKline plc competes in the vaccine space, including collaborations on COVID-19 vaccines and other therapeutic areas that overlap with CureVac's interests.

Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc. is involved in the development of mRNA vaccines and therapeutics, making it a direct competitor in the same technology space as CureVac.

Translate Bio, now a part of Sanofi, focuses on mRNA technologies for vaccines and therapeutics, directly competing with CureVac in the mRNA space.

About

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Show more...

CEO

Dr. Franz-Werner Haas L.L.M., LL.M., LLD, Ph.D.

Employees

764

Country

Germany

ISIN

NL0015436031

Listings

0 Comments

Share your thoughts

FAQ

What is CureVac N.V. stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange CureVac N.V. stocks are traded under the ticker 5CV.MU.

How many employees does CureVac N.V. have?▼

As of July 13, 2026, the company has 764 employees.

In which sector is CureVac N.V. located?▼

CureVac N.V. operates in the Health & Wellness sector.

When did CureVac N.V. complete a stock split?▼

CureVac N.V. has not had any recent stock splits.

Where is CureVac N.V. headquartered?▼

CureVac N.V. is headquartered in Tübingen, Germany.